Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Trial Details

NCT ID
NCT05197881
Phase
NA
Sponsor
Varian, a Siemens Healthineers Company
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Varian Ethos Adaptive Radiation Therapy
Locations (sample)
  • Burmingham, Alabama, United States
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • La Jolla, California, United States|32.84727,-117.2742
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous c…
  • For patients with involved pelvic lymph nodes, the upper border of the CTV nodal volume may not extend above the confluence of the common iliac art…
  • Patients must NOT have had a hysterectomy.
  • Pelvic nodal status is to be confirmed by one or more of the following studies/procedures: PET/CT scan, CT scan, MR Scan, fine needle biopsy, extra…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →